He added that safety findings with extended follow-up were previously published and “were consistent with the ADAURA primary analysis and established profile of osimertinib.”

An update was presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, after a median 33.7 months of follow-up.

Participants either did or did not receive abemaciclib 150 mg twice daily for up to 2 years alongside standard of care ET with an aromatase inhibitor or tamoxifen.

After a median follow-up of 24.1 months, the primary endpoint of investigator-assessed PFS was a median of 24.0 months for the participants who were randomly assigned to receive ribociclib 600 mg/day on a 3 weeks on, 1 week off schedule alongside letrozole or anastrozole plus goserelin.

Although Allison Oakes (Trilliant Health, Brentwood, Tennessee, USA) and co-workers identified a quick rebound in screening rates after the initial pandemic measures, they say that “the longer follow-up time reveals that gaps in preventive cancer screening returned and worsened.”

The authors of a related commentary highlight a few key limitations, such as the relatively short follow-up period, which “limits evaluation of longer-term benefit or toxicity,” and the potential challenge for clinicians to translate the primary outcome into daily practice.

The patients had a median of two lymph nodes affected and the median duration of follow-up was 4.5 years.

They say: “Given that cemiplimab plus chemotherapy showed consistently superior PFS and ORR in all subgroups, longer-term follow-up data are awaited to further inform OS results.”

Choueiri told delegates that “follow-up for the secondary endpoint of [overall survival] is very important and is ongoing.”

The investigator noted, however, that the median follow-up was short – at a respective 14.8 and 15.0 months – and therefore “these data are expected to evolve significantly during follow-up.”

Patients received avelumab for a median of 5.8 months and 34.5% were continuing to receive the PD-L1 inhibitor at the time of analysis, which was conducted at a median follow-up of 13.5 months.

Extended follow-up data from the ADAURA trial show that the disease-free survival benefit with adjuvant osimertinib over placebo continues beyond the 3-year treatment duration in people with EGFR -mutated stage IB–IIIA non-small-cell lung cancer.

However, she pointed out that the current study has a shorter duration of follow-up, at 5.4–5.6 months versus 13 months, and therefore “we need longer follow-up to confirm activity” and toxicity. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

The 5-year follow-up data, published in the Annals of Oncology in 2022, demonstrated the continued durable efficacy of pembrolizumab.

Among people with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, sacituzumab govitecan is associated with significantly improved overall survival relative to standard of care, show data from TROPiCS-02.

Overall survival (OS) was assessed after a median 29.3 months of follow-up and was also significantly improved with rezvilutamide versus bicalutamide.

They add that “[f]uture research evaluating long-term safety of [fertility preservation] in young women with [breast cancer] should ideally include even longer follow-up,” given that the median follow-up times in the current study were 4.0 years in the women who received hormonal fertility preservation and 6.7 years in those who underwent a nonhormonal procedure. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.3677

Adjuvant treatment with atezolizumab is associated with a trend toward improved overall survival relative to best supportive care in people with resected stage II–IIIA non-small-cell lung cancer positive for PD-L1, indicate IMpower010 results.

However, session discussant Linda Martin (University of Virginia, Charlottesville, USA) observed that the “tiny numbers” of patients remaining in the CRT subgroups by the end of PFS follow-up “made it difficult to make too many assumptions” about this outcome.